Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| BIONTECH | 6 | 13 | +0,05 % | ||
| IMMUNITYBIO | 1 | 3 | +0,55 % | ||
| ANAVEX LIFE SCIENCES | 1 | - | +0,39 % | ||
| 4D MOLECULAR THERAPEUTICS | 1 | - | -0,79 % | ||
| VENTYX BIOSCIENCES | 1 | - | +0,22 % | ||
| BIOGEN | - | 54 | -0,46 % | ||
| AMGEN | - | 27 | +0,35 % | ||
| INCYTE | - | 25 | -0,52 % | ||
| REGENERON PHARMACEUTICALS | - | 22 | +0,03 % | ||
| MONTE ROSA THERAPEUTICS | - | 21 | -1,54 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10:30 | Curevac mit SONDERMELDUNG! | Hebelschein-Spekulant | |||
| 10:26 | ANAVEX LIFE SCIENCES CORP zündet - jetzt wird's ernst! | 1 | Maximilian Berger | ||
| Sa | Could Acquiring Ventyx Biosciences Send Eli Lilly Stock Soaring in 2026? | 7 | The Motley Fool | ||
| Sa | 4D Molecular Therapeutics, Inc.: 4DMT Announces New Employment Inducement Grants | 2 | GlobeNewswire (USA) | ||
| Sa | Milliardenhoffnung: BioNTech greift mit Krebsforschung neu an: Goldman Sachs löst Kursschub mit optimistischem Onkologie-Ausblick aus | 2.130 | börsennews.de | Die US-Investmentbank Goldman Sachs hat die Aktie von BioNTech deutlich hochgestuft. Statt auf das abklingende Impfstoffgeschäft konzentriert sich die Bewertung nun auf die wachstumsstarke Pipeline... ► Artikel lesen | |
| Sa | ImmunityBio (IBRX) Rallies on 11th Day, Hits 52-Week High on Strong Clinical Trial Results | 34 | Insider Monkey | ||
| Sa | AbbVie And Genmab: Phase 3 EPCORE DLBCL-1 Trial Shows PFS Gains But No Significant OS Benefit | 470 | AFX News | WASHINGTON (dpa-AFX) - AbbVie (ABBV) and Genmab A/S (GMAB) released results from the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab, a subcutaneously administered, T-cell engaging bispecific... ► Artikel lesen | |
| Fr | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | 11 | GlobeNewswire (USA) | ||
| Fr | Annexon Biosciences: Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| Fr | Lifecore Biomedical, Inc.: Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| Fr | LIFECORE BIOMEDICAL, INC. \DE\ - 8-K, Current Report | 1 | SEC Filings | ||
| Fr | Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| Fr | Xenon Pharmaceuticals Inc.: Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| Fr | After AbbVie and Genmab's ph. 3 survival miss for Epkinly in DLBCL, what's next? | 11 | FiercePharma | ||
| Fr | Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis | 3 | GlobeNewswire (USA) | ||
| Fr | NovaBridge Biosciences - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| Fr | Why ImmunityBio Stock Is Skyrocketing Again Today | 36 | The Motley Fool | ||
| Fr | Genmab down after trial data for AbbVie-partnered Epkinly in B-cell lymphoma | 15 | Seeking Alpha | ||
| Fr | Genmab reports positive phase 3 trial results for epcoritamab | 4 | Investing.com | ||
| Fr | Genmab: Epcoritamab zeigt in Phase-3-Studie verbessertes progressionsfreies Überleben | 9 | Investing.com Deutsch |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .